ClinicalTrials.gov
public full text
Public Domain
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
The underlying goal of this study is to assess \[18F\] CFPyPB PET imaging as a tool to evaluate the activity of the GlyT1 receptors in the brain of Parkinson's Disease (PD) and Alzheimer Disease (AD) research participants.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Bridging Genetics and Precision Medicine in Parkinson’s Disease through GP2#138330
- Bridging Genetics and Precision Medicine in Parkinson's Disease through GP2#134326
- Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives#895630
- Exenatide Treatment in Parkinson's Disease#1182926
- A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease#1127392
Record · ID 1337686
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive